Ignite Creation Date:
2024-05-05 @ 11:58 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00198380
Status:
COMPLETED
Last Update Posted:
2024-03-08
First Post:
2005-09-13
Brief Title:
Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature
Sponsor:
Intergroupe Francophone de Cancerologie Thoracique
Organization:
Intergroupe Francophone de Cancerologie Thoracique
Study Overview
Official Title:
Phase II of Gefitinib IRESSA Administered as First-line Treatment in Patients With Non-resectable Pneumonic-type Adenocarcinoma P-ADC
Status:
COMPLETED
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Pneumonic adenocarcinoma P-ADC is defined as a primary lung ADC with a radiological pneumonic presentation usually referred to histologically as ADC with a mixed-invasive and BAC predominant subtype in the 2004 WHO classification Surgery is the best therapy for resectable tumors since the effectiveness of chemotherapy is disappointing In the advanced P-ADC diffusemultifocal types of BAC epidermal growth factor receptor EGFR tyrosine kinase inhibitors TKIs gefitinib and erlotinib have shown promise with some rapid dramatic responses possibly reflecting specific molecular differences from other non-small cell lung carcinomas
Detailed Description:
We therefore conducted a French multicentric phase II trial IFCT 0401 to evaluate activity and tolerance of gefitinib 250 mgday administered as first line treatment in patients with non-resectable P-ADC
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None